Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour

Inclusion Criteria:

1. Patient aged ≥ 18 years.

2. Patient with histologically confirmed grade 1 or 2 neuroendocrine tumor of themidgut, inoperable or metastatic.

3. Patient eligible for Lu-177 oxodotreotide therapy in accordance with its marketingauthorization.

4. Evidence of progression in the 12 months preceding Lu-177oxodotreotide therapy,confirmed by imaging techniques commonly used in current practice (thoraco-abdomino-pelvic CT and/or liver MRI, Ga-68 DOTA somatostatin analog PET-CT) +/- liver involvement greater than 50%.

5. Disease measurable according to RECIST 1.1 criteria in thoraco-abdomino-pelvic CT +/- liver MRI.

6. Patient affiliated to a social security scheme in France.

7. Patient having signed informed consent prior to study inclusion and prior to anyspecific study procedure.

Exclusion Criteria:

1. Previous treatment with Lu-177 oxodotreotide.

2. Any contraindication to treatment with Lu-177 oxodotreotide.

3. Morbid obesity (BMI > 40).

4. Uncontrolled/unbalanced active inflammatory disease in the 3 months prior toinclusion.

5. Active carcinoid heart disease or other acute cardiovascular event.

6. Active infection not treated within 15 days.

7. Pregnant or breast-feeding woman.

8. Any psychological, family, geographical or sociological condition that preventscompliance with the medical follow-up and/or procedures stipulated in the studyprotocol.

9. Patient deprived of liberty or under legal protection (guardianship, legalprotection).